HK1202313A1 - Methods and compositions for the treatment and diagnosis of bladder cancer - Google Patents

Methods and compositions for the treatment and diagnosis of bladder cancer

Info

Publication number
HK1202313A1
HK1202313A1 HK15102806.3A HK15102806A HK1202313A1 HK 1202313 A1 HK1202313 A1 HK 1202313A1 HK 15102806 A HK15102806 A HK 15102806A HK 1202313 A1 HK1202313 A1 HK 1202313A1
Authority
HK
Hong Kong
Prior art keywords
diagnosis
compositions
treatment
methods
bladder cancer
Prior art date
Application number
HK15102806.3A
Other languages
English (en)
Chinese (zh)
Inventor
Karen Chapman
Joseph Wagner
Michael West
Marcus Lacher
Jennifer Lorrie Kidd
Maria J Prendes
Original Assignee
Oncocyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncocyte Corp filed Critical Oncocyte Corp
Publication of HK1202313A1 publication Critical patent/HK1202313A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
HK15102806.3A 2011-11-15 2015-03-18 Methods and compositions for the treatment and diagnosis of bladder cancer HK1202313A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161559806P 2011-11-15 2011-11-15
PCT/US2012/065353 WO2013074837A1 (en) 2011-11-15 2012-11-15 Methods and compositions for the treatment and diagnosis of bladder cancer

Publications (1)

Publication Number Publication Date
HK1202313A1 true HK1202313A1 (en) 2015-09-25

Family

ID=48430161

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15102806.3A HK1202313A1 (en) 2011-11-15 2015-03-18 Methods and compositions for the treatment and diagnosis of bladder cancer

Country Status (9)

Country Link
US (1) US20140323342A1 (xx)
EP (1) EP2780472A4 (xx)
JP (2) JP2014533493A (xx)
KR (1) KR20140092905A (xx)
CN (1) CN103975078B (xx)
AU (1) AU2012340393B2 (xx)
CA (1) CA2856205A1 (xx)
HK (1) HK1202313A1 (xx)
WO (1) WO2013074837A1 (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2723898A4 (en) * 2011-06-22 2015-09-30 Oncocyte Corp METHOD AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF BUBBLE CANCER
US20150299799A1 (en) 2012-10-05 2015-10-22 Michael Sturzl Method for Detecting an Increased Risk or Incidence of Colorectal Cancer
CN104280547A (zh) * 2013-08-12 2015-01-14 云南师范大学 一种ck15角蛋白及基因的应用方法
CN105624313A (zh) * 2016-03-10 2016-06-01 张艳霞 一种用于肺腺癌诊疗的分子标记物
WO2017214189A1 (en) * 2016-06-06 2017-12-14 Oncocyte Corporation Methods and compositions for detection and diagnosis of bladder cancer
CN110139656A (zh) * 2016-08-05 2019-08-16 纽约州州立大学研究基金会 作为膀胱癌的生物标志物的角蛋白17
CN106916887B (zh) 2017-02-13 2018-06-29 徐州市中心医院 Erh基因在制备膀胱癌诊治产品中的应用
CN109116023B (zh) * 2018-06-14 2021-06-04 郑州大学第一附属医院 一种肺癌标志物抗-mmp12自身抗体及其应用
CN109182292B (zh) * 2018-09-25 2022-02-08 安徽农业大学 一种草莓谷胱甘肽转移酶FaGST基因及其表达蛋白和应用
KR20210120699A (ko) 2020-03-27 2021-10-07 가톨릭대학교 산학협력단 성별에 따른 방광암의 예후 진단용 조성물 및 키트
KR20210120698A (ko) 2020-03-27 2021-10-07 가톨릭대학교 산학협력단 연령에 따른 방광암의 예후 진단용 조성물 및 키트
KR20210125457A (ko) 2020-03-27 2021-10-18 가톨릭대학교 산학협력단 재발 여부에 따른 방광암의 예후 진단용 조성물 및 키트
KR20210128370A (ko) 2020-03-27 2021-10-26 가톨릭대학교 산학협력단 방광암의 예후 진단용 조성물 및 키트
KR20210125456A (ko) 2020-03-27 2021-10-18 가톨릭대학교 산학협력단 전이 여부에 따른 방광암의 예후 진단용 조성물 및 키트
KR20210129616A (ko) 2020-03-27 2021-10-28 가톨릭대학교 산학협력단 병리적 병기에 따른 방광암의 예후 진단용 조성물 및 키트
CN113186284B (zh) * 2021-05-06 2022-01-07 浙江东方基因生物制品股份有限公司 一种核酸-抗体双重癌症检测试剂盒
CN113249445B (zh) * 2021-05-28 2022-01-04 杭州康佰裕医学检验实验室有限公司 核酸-抗体双重癌症检测试剂盒

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6998232B1 (en) * 1999-09-27 2006-02-14 Quark Biotech, Inc. Methods of diagnosing bladder cancer
WO2002068579A2 (en) * 2001-01-10 2002-09-06 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
KR20060031809A (ko) * 2003-06-09 2006-04-13 더 리젠츠 오브 더 유니버시티 오브 미시간 암 치료 및 진단용 조성물 및 방법
WO2008021290A2 (en) * 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
ES2304306B1 (es) * 2007-03-20 2009-07-07 Indas Biotech, S.L.U. Metodo de diagnostico y/o pronostico de cancer vesical.
WO2010004590A2 (en) * 2008-07-09 2010-01-14 Decode Genetics Ehf Genetic variants as markers for use in urinary bladder cancer risk assessment, diagnosis, prognosis and treatment
JP6257125B2 (ja) * 2008-11-17 2018-01-10 ベラサイト インコーポレイテッド 疾患診断のための分子プロファイリングの方法および組成物
CN102326081B (zh) * 2009-02-24 2014-11-19 霍夫曼-拉罗奇有限公司 s-ErbB-3作为癌症标志物的应用
WO2010127399A1 (en) * 2009-05-06 2010-11-11 Walter And Eliza Hall Institute Of Medical Research Gene expression profiles and uses thereof
JP2010268690A (ja) * 2009-05-19 2010-12-02 Nippon Kayaku Co Ltd 抗腫瘍活性を持つ化合物の感受性の判定方法
GB0922437D0 (en) * 2009-12-22 2010-02-03 Cancer Rec Tech Ltd Hypoxia tumour markers
US20110256539A1 (en) * 2010-04-15 2011-10-20 Hai-Su Yang Methods for Detecting Tumor Origin Based on MUC1, MUC2, and CK-17 Expression Levels
US20110262921A1 (en) * 2010-04-23 2011-10-27 Sabichi Anita L Test for the Detection of Bladder Cancer

Also Published As

Publication number Publication date
CN103975078A (zh) 2014-08-06
KR20140092905A (ko) 2014-07-24
AU2012340393B2 (en) 2018-06-14
US20140323342A1 (en) 2014-10-30
WO2013074837A1 (en) 2013-05-23
CA2856205A1 (en) 2013-05-23
JP2014533493A (ja) 2014-12-15
EP2780472A1 (en) 2014-09-24
CN103975078B (zh) 2016-11-09
EP2780472A4 (en) 2015-10-28
AU2012340393A1 (en) 2014-05-22
JP2018102299A (ja) 2018-07-05

Similar Documents

Publication Publication Date Title
HK1199099A1 (en) Methods and compositions for the treatment and diagnosis of cancer
HK1202313A1 (en) Methods and compositions for the treatment and diagnosis of bladder cancer
HK1199100A1 (en) Methods and compositions for the treatment and diagnosis of colorectal cancer
HK1197276A1 (en) Methods and compositions for the treatment and diagnosis of bladder cancer
EP2723924A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF CANCER
EP2890815A4 (en) METHOD FOR THE DIAGNOSIS AND TREATMENT OF CANCER
HK1178074A1 (en) Compositions and methods for the diagnosis and treatment of tumor
GB201115711D0 (en) Phyto-cannabinoids for use in the treatment of cancer
ZA201208815B (en) Methods of treating bladder cancer
EP2688594A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP2621499A4 (en) METHODS OF TREATING ALLERGIC DISEASES
HK1202253A1 (en) Combination treatment of cancer
HK1200739A1 (en) Diagnostic methods and compositions for treatment of cancer
GB2495841B (en) Phytocannabinoids for use in the treatment of breast cancer
EP2714081A4 (en) METHODS, COMPOSITIONS AND KIT FOR CREAM TREATMENT
HK1199290A1 (en) Methods and compositions for the treatment and diagnosis of breast cancer
IL238177A0 (en) Methods and preparations for the treatment of cancer
HK1201045A1 (en) Compositions and methods for the diagnosis and treatment of tumor
IL240560A0 (en) Preparations and methods for tumor diagnosis and treatment
IL275636A (en) Medical combination for cancer treatment
EP2709632A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF SKIN DISEASES
EP2547368A4 (en) METHOD AND COMPOSITIONS FOR CANCER TREATMENT
EP2793875A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF A DIVERTICULOSE
PL2456445T3 (pl) Środek do leczenia chorób skóry
GB201121791D0 (en) Combination treatment of cancer